Opidol

Quick links to important sections

Opidol

Treatment option: Pain, Chronic Pain

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Opidol

This section provides a concise, authoritative overview of the medicinal entity Opidol (Tramadol Hydrochloride), its classification, composition, and general purpose, strictly avoiding details related to dosage, usage instructions, side effects, or commercial information.

Property Description
Active ingredient Tramadol Hydrochloride
Form Tablets, capsules, solution for injection
Pharmacological class Synthetic Central-Acting Analgesic
Common use Relief of moderate to severe pain
Origin Synthetic

Identity and Classification

Opidol is a medicinal product that contains the active ingredient Tramadol Hydrochloride, which is clinically recognized as a synthetic central-acting analgesic. This means the substance is chemically synthesized in a laboratory, establishing its synthetic origin, and its primary pain-relieving effects occur within the central nervous system (CNS), which includes the brain and spinal cord. Tramadol is formally categorized as an analgesic on the Model List of Essential Medicines, reflecting its role in addressing significant pain levels as a differentiating factor from over-the-counter pain relievers. Opidol is a single-ingredient product commonly available in multiple dosage forms, including conventional tablets, extended-release capsules, and a sterile solution for injection in ampoules, facilitating either oral or parenteral route of administration depending on the specific patient setting.


Composition and General Purpose

The core composition of this medicine centers entirely on the compound Tramadol Hydrochloride, which serves as the essential analgesic agent used for the alleviation of moderate to severe pain. Tramadol's effectiveness is characterized by its dual mechanism, which targets pain signals through two separate pathways. It acts as a weak mu -opioid receptor agonist and inhibits the neuronal reuptake of chemical messengers like serotonin and norepinephrine. This mechanism indicates the medicine works by influencing the brain and spinal cord's natural ability to reduce pain signals. The general purpose is to offer effective pain management, such as when a patient requires relief following a medical procedure or managing chronic conditions where pain is substantial. This comprehensive analgesic effect is vital for patients requiring robust pain relief.

Regulatory References

  1. World Health Organization's (WHO) Model List of Essential Medicines

What side effects are possible with Opidol?

Possible side effects and safety information

The safety profile of Opidol (Tramadol Hydrochloride) is defined by officially classified adverse reactions and specific regulatory constraints detailed in government labeling. Adverse effects are organized by frequency and the physiological system affected.

Frequency-Classified Adverse Reactions

Adverse reactions documented in regulatory sources fall into defined frequency categories:

  • Very Common (ge 1/10): This category includes Nausea and Dizziness.
  • Common (ge 1/100 to <1/10): Reactions listed here include Headache, Somnolence (drowsiness), Vomiting, Constipation, and Sweating (Hyperhidrosis).
  • Uncommon to Rare: Less frequent reactions, such as Orthostatic Hypotension, Tachycardia, and Syncope, are documented, alongside serious risks like Seizures and Respiratory Depression.

Serious Adverse Reactions and Safety Constraints

The official label highlights specific serious risks associated with this medicine. These include the potential for life-threatening Respiratory Depression and the risk of Serotonin Syndrome, particularly when used concomitantly with certain other medications. The medication is an opioid agonist with documented risk for abuse and misuse, leading to potential Opioid Use Disorder (OUD) and physical dependence. The risk of seizures is also explicitly noted, even within the recommended dose range.

Population-Specific Safety Notes

The regulatory profile defines constraints for specific populations. The medicine is contraindicated in children younger than 12 years of age. Prolonged use during pregnancy is associated with the risk of Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn. Furthermore, use in the elderly or those with renal/hepatic impairment may require particular caution as defined by official labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Opidol, an opioid analgesic, is a serious, life-threatening emergency primarily characterized by profound central nervous system (CNS) and respiratory depression.

Documented Overdose Manifestations

The most dangerous consequence of overdose is life-threatening respiratory depression (slowed or shallow breathing) which can lead to coma or death. Other signs of a serious overdose include:

  • Extreme sleepiness or inability to be awakened (unresponsiveness).
  • Pinpoint pupils.
  • Limp body and pale, clammy skin.
  • Blue or purple coloration of the lips or fingernails.

Circumstances Increasing Overdose Risk

The risk of a fatal overdose is significantly increased by several factors documented in official regulatory labeling:

  1. Accidental Ingestion: Swallowing even one dose, particularly by a child, can result in a fatal overdose.
  2. Concomitant Use: Using Opidol with other CNS depressants, such as benzodiazepines or alcohol, substantially increases the risk of profound sedation, respiratory depression, coma, and death.
  3. Dose Amount: Overdose risk is associated with ingesting higher doses than prescribed or authorized.

Required Emergency Actions

Immediate medical attention is required for any suspected overdose. Seek emergency medical help (call 911) right away if a person experiences any signs of respiratory problems or unresponsiveness. Emergency treatment must include securing an open airway and may involve administering a pure opioid antagonist, such as naloxone, to counteract the respiratory depression. Do not wait for symptoms to worsen.

Therapeutic Uses of Opidol

What Opidol Treats: Main Uses and Benefits

Opidol (Tramadol Hydrochloride) is an analgesic primarily employed to provide supportive symptomatic relief across clinical settings marked by significant patient discomfort. Its use is focused on addressing the intensity of the symptoms that interfere with daily functioning. This medication is utilized for the management of pain that is severe enough to require an opioid analgesic.


Key Therapeutic Applications

This medication is commonly used for the short-term management of intense pain, such as the symptoms related to physical discomfort experienced following surgical procedures or a significant trauma. Opidol is also relevant in conditions characterized by periods of heightened symptoms, including severe osteoarthritis or complex cancer-related pain (palliative care). It is applied when symptoms related to physical discomfort are high (moderate to severe) and create noticeable interference with daily stability.

The primary benefit is that it may assist in managing distressing symptom manifestations that lead to functional strain. By easing the symptom intensity, Opidol may offer symptomatic relief that helps patients cope more steadily with symptom fluctuations and assists with maintaining functional stability.


Quick Fact: Relief for Intense Pain
Symptom Severity: Moderate to Severe
Typical Contexts: Postoperative, Trauma, Chronic Syndromes
Benefit: Supports functional stability and coping

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility and Contraindications

The eligibility for Opidol (Tramadol Hydrochloride) is strictly defined by regulatory authorities based on specific population categories and pre-existing health conditions. Use is contraindicated (prohibited) in several key groups.

Absolute Prohibitions

Opidol must not be used by:

  • Children younger than 12 years of age.
  • Individuals younger than 18 years following tonsillectomy and/or adenoidectomy.
  • Patients with significant respiratory depression or uncontrolled epilepsy.
  • Patients with acute intoxication from alcohol or other central-acting substances.
  • Patients currently taking or having recently taken (within 14 days) Monoamine Oxidase Inhibitors (MAOIs).

Restricted and Conditional Use

Restrictions apply to other populations where use is not recommended:

  • Pregnancy: Not recommended due to the risk of neonatal opioid withdrawal syndrome.
  • Lactation/Breastfeeding: Long-term use is generally contraindicated.
  • Organ Function: Use of extended-release forms is not recommended for patients with severe hepatic (liver) impairment or severe renal (kidney) impairment (creatinine clearance < 30 mL/min). Use requires greater caution in patients over 75 years of age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes documented interaction patterns for Opidol (Tramadol Hydrochloride), focusing strictly on regulatory labeling and constraints.

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated, and Opidol must not be used within 14 days of stopping MAOI treatment. This prohibition is due to the documented risk of severe Serotonin Syndrome and seizures.

Pharmacodynamic and Substance Interactions

Category Interacting Substances Official Regulatory Constraint
CNS Depression Other Opioids, Benzodiazepines, and Alcohol Risk of profound sedation, respiratory depression, coma, and death due to additive effects.
Serotonin Risk SSRIs, SNRIs, Triptans, and other serotonergic drugs Increased risk of Serotonin Syndrome and elevated seizure risk.

Metabolic and Exposure Interactions

The substance's metabolism is influenced by cytochrome P450 enzymes. Co-administration with CYP2D6 inhibitors (e.g., fluoxetine) is documented to increase Tramadol plasma exposure while decreasing the concentration of the active M1 metabolite. Conversely, strong CYP3A4 inducers such as Carbamazepine significantly reduce the analgesic effect by increasing clearance, leading to the regulatory constraint that co-administration is not recommended. Furthermore, specific population warnings exist, noting that the risk of respiratory depression is heightened in the elderly and in ultra-rapid CYP2D6 metabolizers when co-administered with CNS depressants.

Mechanism of Action

Opidol, which is tramadol hydrochloride, exerts its pharmacological action in the central nervous system via a dual mechanism. The parent compound and its pharmacologically active metabolite, O-desmethyl-tramadol (M1), function as agonists at the mu-opioid receptor left(mu -OR ight). The binding of these molecules to the mu -OR — a G-protein-coupled receptor — initiates the inhibitory cascade. This coupling inhibits adenylate cyclase activity, leading to a decrease in intracellular cyclic adenosine monophosphate (cAMP) levels. This intracellular change ultimately results in reduced neuronal excitability and decreased release of pronociceptive neurotransmitters, modulating signal transmission in the spinal cord and supraspinal structures.

Simultaneously, the parent compound acts as a weak inhibitor of the neuronal reuptake of the monoamine neurotransmitters serotonin (5-HT) and norepinephrine (NE). This reuptake inhibition increases the concentration of 5-HT and NE within the synaptic cleft, enhancing the activity of the descending pain inhibitory pathways that project from the brainstem to the dorsal horn of the spinal cord. This combined mu -OR agonism and monoamine reuptake inhibition constitutes the complete system-level physiological modulation.

Dosage and Administration Information

Opidol (Tramadol Hydrochloride) is approved for administration via Oral, Parenteral (intravenous, intramuscular, or subcutaneous injection), and Rectal routes, corresponding to its various dosage forms including immediate-release tablets, extended-release capsules, and solution for injection.

The standard adult dosing regimen for Immediate-Release (IR) forms typically involves 50 mg to 100 mg per dose, administered every 4 to 6 hours as needed. The total adult daily dosage for IR forms is not to exceed 400 mg. Extended-Release (ER) formulations are administered once daily with a maximum labeled dose of 300 mg. Oral forms may be taken with or without food.

A key procedural instruction is that ER tablets and capsules must be swallowed whole and must not be crushed, chewed, or split. Furthermore, the oral solution must be accurately measured using a calibrated dosing device.

Dosing requires adjustment for specific populations. In older adults (over 75 years), the maximum daily dose for IR forms is generally limited to 300 mg. Standard clinical practice involves a reduced dosing frequency for patients with severe renal or hepatic impairment, often requiring the IR dosing interval to be extended to 12 hours; ER formulations are not recommended in these populations. When discontinuing Opidol, the protocol involves the dose being gradually tapered rather than stopped abruptly.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Opidol

This overview describes the types of studies that have been conducted to evaluate Opidol (Tramadol Hydrochloride) and what findings these studies reported, focusing only on the official research landscape. This summary is not clinical advice and does not include information about dosing, side effects, or safety.


Research Evidence for Acute Pain Management

The evidence supporting the study of Opidol in acute settings primarily comes from short-term Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies are conducted during periods of increased symptom activity, such as immediately following surgical procedures or trauma.

Researchers primarily examined patient-reported outcomes related to physical discomfort, specifically measuring the change in pain intensity using validated scales, the time reported for pain relief onset, and the need for additional pain medication during the short follow-up period. Studies reported measurements related to change in pain intensity over the initial hours and days following administration.


Research Evidence for Chronic Pain Syndromes

Research into Opidol was studied for managing chronic pain—such as that associated with severe osteoarthritis or chronic low back pain—using controlled trials and subsequent systematic reviews. These studies focus on conditions marked by functional limitations and symptoms that may vary in intensity.

Studies monitored how symptoms evolved in the observed populations. Findings indicate that measurements of pain intensity and function were taken, but authoritative reviews have noted that the data often described changes that was associated with small measurements or evidence remains limited regarding clinically meaningful improvement. The certainty remains low regarding outcomes reflecting daily functioning or activity level over long time frames, a point often cited in regulatory scientific literature.


Long-Term Studies and Follow-Up Duration

The evidence has primarily focused on research exploring short-term symptom changes and monitoring responses over defined time intervals. Data show patterns related to how symptoms evolved over these defined time intervals. However, regulatory scientific sources routinely emphasize that long-term effects are not fully established. There is limited information for long-term outcomes that look at the durability of any observed response or the overall course of treatment for periods exceeding one year.

Key Studies & References Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects (General Chronic Pain Evidence)

Frequently Asked Questions (FAQ)

Common questions about Opidol (FAQ)


Q: How quickly does Opidol start working?

A: Official information indicates that immediate-release formulations of Opidol typically begin to offer measurable relief approximately within one hour after administration. The peak effect, when the medicine works most strongly, generally occurs within two to four hours after administration.

Q: How long do the effects of Opidol last?

A: The pain-relieving effects of the immediate-release formulation are generally reported to last for approximately six hours. Extended-release formulations are specifically designed to provide effects that last for up to 24 hours, consistent with once-daily administration.

Q: Does Opidol affect sleep?

A: Official regulatory documents list somnolence (drowsiness) as a common side effect of Opidol. Because the medicine is associated with central nervous system effects, this may include changes in sleep patterns or feelings of tiredness.

Q: Can Opidol be taken with alcohol?

A: Official warnings state that taking Opidol with alcohol increases the risk of very serious side effects, including profound sedation and life-threatening respiratory depression. Regulatory warnings formally document the risk of co-administration with alcohol.

Q: Are there any food restrictions while taking Opidol?

A: Immediate-release oral forms of Opidol may be taken with or without food. However, some regulatory sources advise caution regarding consumption of grapefruit and grapefruit juice, due to the potential for increased exposure, which may increase the likelihood of side effects.

Q: What happens if I miss a dose of Opidol?

A: Regulatory guidance emphasizes that Opidol should be taken exactly as prescribed. If a dose is missed, a patient is instructed not to take a double dose to make up for the missed one. The decision about how to manage a missed dose should be based on the directions provided by the prescribing healthcare professional.

Q: What should I do if a side effect of Opidol is bothersome?

A: Official patient information describes that side effects that are severe or persistent should be discussed with a healthcare professional. Patients are also encouraged to report suspected adverse effects through official government reporting schemes.

Q: Does Opidol affect fertility?

A: Regulatory documents mention risks during pregnancy and lactation. While research studies in animals have shown that Opidol may have adverse effects on fertility, the full impact on human reproductive health is not clearly defined in standard patient labeling.

Q: What happens when Opidol wears off?

A: When the medicine is stopped, official protocol advises that the dose be gradually tapered (reduced slowly) because abrupt cessation is associated with withdrawal symptoms. These symptoms can include nervousness, sweating, and difficulty sleeping.

Q: Can Opidol be taken with grapefruit juice?

A: Regulatory guidance advises caution regarding consumption of grapefruit and grapefruit juice. This is because grapefruit is described as potentially increasing the amount of medicine in the blood, which may increase the likelihood of side effects.

Q: What is the difference between Opidol and [similar sounding drug]?

A: Opidol (Tramadol) is defined as a synthetic central-acting analgesic with a dual mechanism of action. This means it works through two pathways: by acting as a weak opioid on the mu-receptors and by inhibiting the reuptake of chemical messengers like serotonin. Similar medications may belong to different pharmacological classes and may function through different pathways.

Q: Can Opidol cause hair loss?

A: Official regulatory documents list hair disorder, or hair loss, as an uncommon to rare side effect of Opidol.

Q: Can Opidol be split in half?

A: Official product information mandates that extended-release tablets and capsules must be swallowed whole and must not be crushed, chewed, or split. For immediate-release tablets, splitting is generally only supported if the tablet is scored (has a line in the middle) and if specific product information allows it.

Q: Do I need a prescription for Opidol?

A: Yes, Opidol is classified as a controlled substance (Schedule IV) by the U.S. federal government and similar regulatory bodies globally. This classification indicates that the medicine requires a prescription from a licensed healthcare provider before it can be dispensed.

Q: Can Opidol be used for anxiety?

A: Opidol is officially approved for the relief of moderate to severe pain. Its regulatory labeling does not list anxiety or any other psychiatric condition as an approved use or indication.

Q: Does Opidol have a generic version?

A: Yes, regulatory records, such as the FDA Orange Book, confirm that generic versions of Opidol (which contain the active ingredient Tramadol Hydrochloride) have been approved for use.

Q: Is Opidol safe to use long-term?

A: Regulatory scientific sources state that long-term effects are not fully established and that there is limited information for long-term outcomes exceeding one year. Any decision regarding long-term use should be based on professional evaluation.

Q: What are the signs of an allergic reaction to Opidol?

A: Signs of a serious allergic reaction, as described in official labeling, can include hives, difficulty breathing, swelling of the face, lips, tongue, or throat, and severe skin reactions such as blistering or peeling. These effects, if observed, are serious and require immediate attention.

Q: How is Opidol eliminated from the body?

A: Opidol and its pharmacologically active metabolites are primarily eliminated from the body via the kidneys (urine excretion). This is why regulatory guidance advises caution and dose adjustments for patients with severe kidney impairment.

Q: Is there any research about Opidol and heart health?

A: While studies primarily focus on pain, official labeling documents side effects related to the heart and circulation, such as Orthostatic Hypotension (a drop in blood pressure upon standing) and Tachycardia (a fast heart rate).

Q: Can Opidol affect blood pressure?

A: Yes, official safety information documents rare side effects such as Orthostatic Hypotension (a form of low blood pressure). Some sources have also noted that it may be linked to changes in both high and low blood pressure.

Q: Does Opidol cause dry mouth?

A: Yes, dry mouth is listed as a documented, though not always common, side effect of Opidol in official safety information.

Q: Is Opidol addictive?

A: Regulatory information notes the potential for abuse and misuse, which can lead to the development of Opioid Use Disorder (OUD) and physical dependence. This risk is one reason why the medicine is classified as a controlled substance.

Q: What if Opidol doesn't seem to be working?

A: Official patient guidance states that the patient should tell their care team if their pain does not go away, gets worse, or if they develop a different type of pain. Any adjustment to use requires consultation with a healthcare professional.

Q: Is Opidol safe for people with diabetes?

A: While Opidol is not absolutely contraindicated in patients with diabetes, some official data and safety reports have noted a rare risk of hypoglycemia (low blood sugar). This potential for hypoglycemia is a consideration described in the official safety information.

Q: Is Opidol a vitamin or supplement?

A: No, Opidol is a prescription medicine. It is classified as a synthetic central-acting analgesic, not a vitamin, herbal remedy, or nutritional supplement.

Q: Does Opidol show up on a drug test?

A: Yes, Opidol and its active metabolite can be detected in some drug screenings. While it may not appear on a standard panel, it can be detected in specific drug tests, such as an extended opioid panel.

How should Opidol be stored and disposed of?

Storage and Disposal Requirements for Opidol

Official regulatory documents define specific conditions for storing and disposing of Opidol (Tramadol Hydrochloride) to maintain product integrity and ensure safety.

Storage Conditions

Opidol must be stored at controlled room temperature, typically between 20 C and 25 C. The medicine must be kept in its original container to maintain its stability and to ensure protection from light. Due to the significant safety risks of accidental ingestion, Opidol must be stored securely and out of the sight and reach of children at all times. Do not store the medicine in areas with excessive heat or moisture.

Disposal Instructions

Disposal of unused or expired Opidol must follow local regulations. The preferred method is to utilize a drug take-back program or pharmacy drop-off site. If a take-back program is unavailable, regulators permit safe disposal in the household trash by mixing the tablets with an unappealing substance, placing the mixture in a sealed bag, and discarding it. Opidol should not be flushed down a toilet unless explicitly included on an official flush list.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Opidol found in:

A-Z Index: